Pfizer
NEWS
Now that Reckitt Benckiser has walked away from a deal, GlaxoSmithKline is now the favorite to acquire Pfizer’s consumer health business.
The head of GlaxoSmithKline’s pharmaceuticals division is pushing to cut its budget by 20 percent.
The FDA granted a Priority Review designation to Pfizer and partner Astellas Pharma for expanded use of Xtandi in prostate cancer treatment.
Tecentriq’s Phase III results gives Genentech a lead for potentially becoming the first-line treatment for squamous non-small cell lung cancer.
Companies that have a strong focus on developing drugs that target messenger RNA (mRNA) may be ahead of the curve when it comes to potentially tapping into a lucrative market space.
On April 23, the FDA’s arthritis advisory committee will take another look at Eli Lilly’s re-submission for their moderate-to-severe rheumatoid arthritis drug.
Biogen is buying Pfizer’s PF-04958242, a first-in-class, Phase IIb-ready drug to treat several neurological and psychiatric diseases, including schizophrenia.
Hikma Pharmaceuticals generic version of Advair has hit a stumbling block with the FDA.
Realm Therapeutics announced today that its PR013, failed to show efficacy in its Phase II trial for allergic conjunctivitis.
JOBS
IN THE PRESS